Drug Design and Discovery in Alzheimer s Disease

Produk Detail:
  • Author : Atta-ur-Rahman
  • Publisher : Elsevier
  • Pages : 784 pages
  • ISBN : 0128039604
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Drug Design and Discovery in Alzheimer s Disease

Download or Read online Drug Design and Discovery in Alzheimer s Disease full in PDF, ePub and kindle. this book written by Atta-ur-Rahman and published by Elsevier which was released on 27 June 2015 with total page 784 pages. We cannot guarantee that Drug Design and Discovery in Alzheimer s Disease book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets

Drug Design and Discovery in Alzheimer s Disease

Drug Design and Discovery in Alzheimer   s Disease
  • Author : Atta-ur-Rahman,Muhammad Iqbal Choudhary
  • Publisher : Elsevier
  • Release : 27 June 2015
GET THIS BOOK Drug Design and Discovery in Alzheimer s Disease

Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery.

Drug Discovery and Development for Alzheimer s Disease 2000

Drug Discovery and Development for Alzheimer s Disease  2000
  • Author : Howard M. Fillit, MD,Alan W. O'Connell, PhD
  • Publisher : Springer Publishing Company
  • Release : 03 January 2002
GET THIS BOOK Drug Discovery and Development for Alzheimer s Disease 2000

This prestigious volume presents the findings of an international group of academic and biotechnological researchers. Topics range from early detection programs focusing on genetic factors, novel probes for detecting B-amyloid in the living brain, and the use of telephonic screening and MRI's to the diversity of therapeutic areas such as antioxidants, estrogen agonists and various anti-B-amyloid and anti-tangle approaches. The volume is still an indispensable resource for the psychogeriatrician, psychiatrist, clinical investigator, and neurobiologist, and a must for medical libraries.

Alzheimer s Disease Drug Development

Alzheimer s Disease Drug Development
  • Author : Jeffrey Cummings,Jefferson Kinney,Howard Fillit
  • Publisher : Cambridge University Press
  • Release : 31 March 2022
GET THIS BOOK Alzheimer s Disease Drug Development

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
  • Author : Adeboye Adejare
  • Publisher : Academic Press
  • Release : 20 September 2016
GET THIS BOOK Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer’s Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies,

Frontiers in CNS Drug Discovery

Frontiers in CNS Drug Discovery
  • Author : Atta-ur- Rahman,M. Iqbal Choudhary
  • Publisher : Bentham Science Publishers
  • Release : 19 December 2017
GET THIS BOOK Frontiers in CNS Drug Discovery

Frontiers in CNS Drug Discovery is a book series devoted to publishing reviews which highlight the latest advances in drug design and discovery for disorders of the central nervous system (CNS). Eminent scientists write contributions on all areas of CNS drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The book series is essential reading for all pharmaceutical scientists involved in CNS drug design and discovery

Preclinical and clinical issues in Alzheimer s disease drug research and development

Preclinical and clinical issues in Alzheimer   s disease drug research and development
  • Author : Cesare Mancuso,Silvana Gaetani
  • Publisher : Frontiers Media SA
  • Release : 03 March 2015
GET THIS BOOK Preclinical and clinical issues in Alzheimer s disease drug research and development

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive cognitive dysfunction and memory loss, inability to perform the activities of daily living and mood disorders. According to the so-called “amyloid cascade hypothesis”, amyloid-ß- peptide (Aß), produced by beta- and gamma- secretase-mediated cleavages of the amyloid precursor protein (APP), plays a pivotal role in the pathogenesis of AD. Aß was also shown to contribute to AD pathology by stimulating the hyperphosphorylation of tau which is responsible for

Discovery and Development of Neuroprotective Agents from Natural Products

Discovery and Development of Neuroprotective Agents from Natural Products
  • Author : Goutam Brahmachari
  • Publisher : Elsevier
  • Release : 18 May 2017
GET THIS BOOK Discovery and Development of Neuroprotective Agents from Natural Products

Discovery and Development of Neuroprotective Agents from Natural Products draws together global research on medicinal agents from natural sources as starting points for the design of neuroprotective drugs. From the prediction of promising leads and identification of active agents to the extraction of complex molecules, the book explores a range of important topics to support the development of safer, more economical therapeutics for these increasingly prevalent diseases. Beginning with an overview of current developments in the field, the book goes

Computational Approaches for Identifying Drugs Against Alzheimer s Disease

Computational Approaches for Identifying Drugs Against Alzheimer s Disease
  • Author : Radha Mahendran,Suganya Jeyabaskar,Astral Gabriella Francis
  • Publisher : Anchor Academic Publishing
  • Release : 01 May 2017
GET THIS BOOK Computational Approaches for Identifying Drugs Against Alzheimer s Disease

Alzheimer’s disease is the most common form of dementia which is incurable. Although some kinds of memory loss are normal during aging, these are not severe enough to interfere with the level of function. ß-Secretase is an important protease in the pathogenesis of Alzheimer’s disease. Some statine-based peptidomimetics show inhibitory activities to the ß-secretase. To explore the inhibitory mechanism, molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies on these analogues were performed. Quantitative structure-activity relationship (QSAR) modeling

Emerging Drugs and Targets for Alzheimer s Disease

Emerging Drugs and Targets for Alzheimer s Disease
  • Author : Ana Martinez
  • Publisher : Royal Society of Chemistry
  • Release : 07 May 2010
GET THIS BOOK Emerging Drugs and Targets for Alzheimer s Disease

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression

Biomarkers for Alzheimer s Disease Drug Development

Biomarkers for Alzheimer s Disease Drug Development
  • Author : Robert Perneczky
  • Publisher : Unknown
  • Release : 04 July 2022
GET THIS BOOK Biomarkers for Alzheimer s Disease Drug Development

This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimers disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimers disease, cutting-edge developments in neuropathology and their relevance for Alzheimers disease trials, novel genomic strategies for biomarker development, and related

Alzheimer s Disease Drug Development

Alzheimer s Disease Drug Development
  • Author : Jeffrey Cummings,Jefferson Kinney,Howard Fillit
  • Publisher : Cambridge University Press
  • Release : 31 March 2022
GET THIS BOOK Alzheimer s Disease Drug Development

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

Frontiers in Clinical Drug Research Alzheimer Disorders

Frontiers in Clinical Drug Research   Alzheimer Disorders
  • Author : Atta-ur-Rahman
  • Publisher : Bentham Science Publishers
  • Release : 24 November 2014
GET THIS BOOK Frontiers in Clinical Drug Research Alzheimer Disorders

Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders. Frontiers in Clinical Drug Research - Alzheimer

Structure Based Drug Design for Diagnosis and Treatment of Neurological Diseases

Structure Based Drug Design for Diagnosis and Treatment of Neurological Diseases
  • Author : Rona R. Ramsay,Giuseppe Di Giovanni
  • Publisher : Frontiers Media SA
  • Release : 24 March 2017
GET THIS BOOK Structure Based Drug Design for Diagnosis and Treatment of Neurological Diseases

European Cooperation in Science and Technology (COST) supports the collaboration of nationally-funded science and technology research through the creation of networks. COST is the longest-running European framework enhancing cooperation among researchers, engineers and scholars across Europe. The COST Action CM1103 “Structure-based drug design for diagnosis and treatment of neurological diseases: dissecting and modulating complex function in the monoaminergic systems of the brain” is a good example of the advances possible through interdisciplinary collaboration on difficult problems. COST Action CM1103 brought